AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

Amber Tong

Marc Dunoyer has unveiled his first buyout since taking over at Alexion — one that his predecessors have lassoed in before a $39 billion merger made …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight in­to risky field

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data